Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Rating of “Buy” by Brokerages

Monopar Therapeutics Inc. (NASDAQ:MNPR) has been given an average recommendation of “Buy” by the thirteen ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $107.00.

A number of equities research analysts recently commented on MNPR shares. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st. Chardan Capital reissued a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a research note on Monday, March 30th. Wall Street Zen raised Monopar Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, January 21st. Finally, BTIG Research reiterated a “buy” rating and issued a $104.00 price objective on shares of Monopar Therapeutics in a research report on Monday, February 23rd.

Monopar Therapeutics Price Performance

Shares of NASDAQ MNPR opened at $64.95 on Thursday. The stock has a fifty day moving average price of $57.07 and a 200 day moving average price of $65.20. Monopar Therapeutics has a 1-year low of $28.40 and a 1-year high of $105.00. The company has a market cap of $435.17 million, a PE ratio of -34.18 and a beta of 1.49.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41. Analysts anticipate that Monopar Therapeutics will post -3.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Monopar Therapeutics

A number of large investors have recently made changes to their positions in MNPR. Janus Henderson Group PLC boosted its holdings in Monopar Therapeutics by 2.3% during the fourth quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock worth $85,908,000 after buying an additional 30,042 shares in the last quarter. RA Capital Management L.P. increased its holdings in Monopar Therapeutics by 30.5% in the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after buying an additional 156,000 shares in the last quarter. Siren L.L.C. increased its holdings in Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after buying an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC lifted its position in shares of Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after acquiring an additional 30,370 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in shares of Monopar Therapeutics during the 3rd quarter valued at approximately $18,904,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.